Last reviewed · How we verify
No Intrathecal Morphine
No Intrathecal Morphine is a Small molecule drug developed by University Health Network, Toronto. It is currently in Phase 3 development. Also known as: Kadian.
This is a clinical trial protocol designation indicating the absence of intrathecal morphine administration, rather than a drug itself.
Intrathecal morphine has been studied for its effectiveness in managing various types of pain, including intractable, breakthrough, and chronic pain, as well as pain associated with cesarean delivery. It is administered as part of a combination treatment that may include bupivacaine and a drug dose adjustment.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | No Intrathecal Morphine |
|---|---|
| Also known as | Kadian |
| Sponsor | University Health Network, Toronto |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
The term 'No Intrathecal Morphine' appears to be a trial arm or control group identifier used by University Health Network in a Phase 3 study, likely comparing outcomes in patients who do not receive morphine delivered directly into the cerebrospinal fluid via intrathecal injection. This is a study design element rather than a pharmaceutical agent with its own mechanism of action.
Approved indications
Common side effects
Key clinical trials
- Quality of Postoperative Analgesia and Functional Recovery After Elective Cesarean Delivery (NA)
- Observational Retrospective Study on Spinal Analgesia in Laparoscopic and Laparotomic Hysterectomy
- Intrathecal Morphine for Recovery and Outcomes After VATS (NA)
- Spinal Anesthesia For Enhanced Recovery After Liver Surgery (NA)
- Intravenous Nalbuphine for Prevention of Intrathecal Morphine-induced Nausea and Vomiting in Patients Undergoing Cesarean Section: A Double-blind, Randomized Controlled Trial. (NA)
- Use of Driving Tests to Evaluate Patient Performance on Oral Opioids
- Intravenous Methadone Versus Intrathecal Morphine for Analgesia Following Cesarean Delivery (PHASE4)
- Post-Operative Urinary Retention on Revision Knee Arthroplasty: the Role of Intrathecal Morphine (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- No Intrathecal Morphine CI brief — competitive landscape report
- No Intrathecal Morphine updates RSS · CI watch RSS
- University Health Network, Toronto portfolio CI
Frequently asked questions about No Intrathecal Morphine
What is No Intrathecal Morphine?
How does No Intrathecal Morphine work?
Who makes No Intrathecal Morphine?
Is No Intrathecal Morphine also known as anything else?
What development phase is No Intrathecal Morphine in?
Related
- Manufacturer: University Health Network, Toronto — full pipeline
- Also known as: Kadian
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing